1Wenger LD. Bacterial meningitis in the United States [J]. Infect Dis 1990,162:1316-1323.
2Hoan-Jong Lee. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy Children and in children at increased risk of pneumococcal infection [J].Vaccine 1995,13(16):1535-1538.
3Shapiro ED, Austrain R. Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut[J].Infect Dis 1994,169:212-214.
4Fedson DS,Musher DM,Eskola J. Penumococcal vaccine[M].Vaccines,3rd edi,W. B. Saunders CO. 1999,553-667.
5Maurice A. Type-specific antibody response of volunteers immunized with 23-valent pneumococcal polysaccharide vaccine[J]. Infect Dis 1985,151:749-750.
6Chi-Jen Lee. Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry[J]. Bioloyicals2002,30(2):97-104.
7ShenSJ.Serotypes and epidemiological study ofpneumococcal infection in 18provinces（cities）in China[J].中华流行病学杂志,1989,10(3):133-137.
8D Bogaert, P W M. Hennansa, Pneumococcal vaccines: an update on current strategi-Es[J]. Vaccine 22(2004) 2209-2220.
9Hoan-Jong Lee. Immunogenicity and safety of a 23-valent pneumococcal polysacch- aride vaccine in healthy Children and in children at increased risk of peneumococcal infection[J]. Vaccine 1995,13(16) :1535-1538.
10Shapiro ED, Austrain R. Serotypes responsible for invasive Streptococcus pneumo-niae infections among children in Connecticut[ J ].Infect Dis 1994,169:212-214.
